

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2752-43

Maertens et al

C# M#

Serial No. 09/851,138

Group Art Unit: 1648

Filed: May 9, 2001

Examiner: Li

Date: December 20, 2002

Title: NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS
PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENTSAssistant Commissioner for Patents
Washington, DC 2023116485
RECEIVED

DEC 26 2002

TECH CENTER 1600/2900

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☒ **Correspondence Address Indication Form Attached.****Fees are attached as calculated below:**

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 400.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

Subtotal \$ 400.00

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: Amendment; Copy of Claims from U.S. Patent No. 6,180,768; Two-Month Extension Fee 0.00

TOTAL FEE ENCLOSED \$ 400.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
BJS:plb

NIXON & VANDERHYE P.C.
By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Maertens et al

Serial No. 09/851,138

Filed: May 9, 2001

For: NEW SEQUENCES OF HEPATITIS C VIRUS
GENOTYPES AND THEIR USE AS PROPHYLACTIC,
THERAPEUTIC AND DIAGNOSTIC AGENTS

Atty. Ref.: 2752-43

Group: 1648

Examiner: Li

December 20, 2002

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RECEIVED

DEC 26 2002

TECH CENTER 1600/2900

AMENDMENT

Responsive to the Office Action dated September 20, 2002, entry and
consideration of the following amendments and remarks are requested.

IN THE CLAIMS

Amend the claims as follows:

64. (Amended) A polynucleic acid which is selected from:

Canceled (i) a polynucleic acid encoding an HCV polyprotein comprising in its amino acid
sequence at least one of the following amino acid residues; L186, G217, C252, A254,
G290, W293, H295, with said notation being composed of a letter representing the
amino acid residue by its one-letter code, and a number representing the amino acid
numbering as shown in Table 1,

(ii) a part of said polynucleic acid of (i) which is unique to HCV type 10, or, to the

12/23/2002 WASFAW1 00000040 09851138

01 FC:1252

400.00 OP